Clinical Trial Update: Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients [Phase 2]

View source ↗

Summary

This update reports the completion of Bayer-sponsored Phase II trial evaluating sorafenib in Japanese patients with anaplastic or medullary thyroid carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Medullary Thyroid Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Thyroid Carcinoma | Phase 2 | Status: COMPLETED